Movatterモバイル変換


[0]ホーム

URL:


SG11201908472VA - Compositions and methods for activating nk cells - Google Patents

Compositions and methods for activating nk cells

Info

Publication number
SG11201908472VA
SG11201908472VASG11201908472VASG11201908472VASG 11201908472V ASG11201908472V ASG 11201908472VASG 11201908472V ASG11201908472V ASG 11201908472VASG 11201908472V ASG11201908472V ASG 11201908472VA
Authority
SG
Singapore
Prior art keywords
international
cells
methods
pct
activating
Prior art date
Application number
Inventor
Anahid Jewett
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ CaliforniafiledCriticalUniv California
Publication of SG11201908472VApublicationCriticalpatent/SG11201908472VA/en

Links

Classifications

Landscapes

Abstract

PUBLISHEDUNDER THE PATENT COOPERATION TREATY (PCT) Hu omit VIII °nolo HE oimIE () International Publication Number WO 2018/152340 Al WIPO I PCT (51) International Patent Classification: A61P 35/00 (2006.01) Cl 2N 5/078 (2010.01) A61K 35/15 (2015.01) A61K 35/32 (2015.01) A61K 35/17 (2015.01) A61K 35/741 (2015.01) (21) International Application Number: PCT/US2018/018389 (22) International Filing Date: 15 February 2018 (15.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/459,397 15 February 2017 (15.02.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventor: JEWETT, Anahid; 24913 Knollwood Land, Valencia, CA 91355 (US). (74) Agent: HALSTEAD, David P. et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: 71' with international search report (Art. 21(3)) 1-1 013 O (57) : The present application relates to methods of activating a NK cells in vitro, ex vivo, and/or in vivo by an osteoclast cell 0 (OC) and/or a dendritic cell, and methods of treating disease using these activated NK cells. (12) INTERNATIONAL APPLICATION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) (54) Title: COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS
SG11201908472V2017-02-152018-02-15Compositions and methods for activating nk cellsSG11201908472VA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201762459397P2017-02-152017-02-15
PCT/US2018/018389WO2018152340A1 (en)2017-02-152018-02-15Compositions and methods for activating nk cells

Publications (1)

Publication NumberPublication Date
SG11201908472VAtrue SG11201908472VA (en)2019-10-30

Family

ID=63169632

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201908472VSG11201908472VA (en)2017-02-152018-02-15Compositions and methods for activating nk cells

Country Status (9)

CountryLink
US (3)US20200306300A1 (en)
EP (1)EP3582856A4 (en)
JP (2)JP7374769B2 (en)
KR (1)KR20190129046A (en)
CN (1)CN110799201A (en)
AU (1)AU2018221745A1 (en)
CA (1)CA3059058A1 (en)
SG (1)SG11201908472VA (en)
WO (1)WO2018152340A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2020102360A1 (en)*2018-11-132020-05-22Cn.Usa Biotech Holdings, Inc.Compositions containing an expanded and enriched population of superactivated cytokine killer t cells and methods for making same
EP3982983A4 (en)*2019-06-142023-11-15G Tech Bio LLCActivated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
WO2021022124A1 (en)*2019-08-012021-02-04The Regents Of The University Of CaliforniaSystems and methods for evaluating nk cells
CA3144018A1 (en)*2019-08-052021-02-11The Board Of Trustees Of The Leland Stanford Junior UniversityManipulation and use of antigen-specific regulatory t cells
CN111235106B (en)*2019-08-302022-08-05武汉大学 A kind of Aptamer-CD3+ T cell targeting tumor cells and its construction method and application
CN112266413A (en)*2020-10-222021-01-26中国人民解放军海军军医大学Factors, feeder cell lines and methods for expanding NK cells and enhancing killing activity thereof
KR102698871B1 (en)*2021-09-102024-08-28이종균Biological composition for preventing or treating cancer comprising dendritic cells, natural killer cells and cytotoxic T cells
WO2023114445A1 (en)*2021-12-162023-06-22The Regents Of The University Of CaliforniaPrevention of bone loss
KR102472076B1 (en)*2021-12-162022-11-30주식회사 아리아코스메틱Manufacturing method for cosmetic with microbiome lactic acid bacteria using NK cell culture medium composition
CN115537397B (en)*2022-12-022023-03-24广东先康达细胞库有限公司NK cell induction culture medium and culture method thereof
CN119410580A (en)*2024-12-042025-02-11潍坊吉涛医学科技有限公司 A method for in vitro expansion and cultivation of NK cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5587384A (en)1994-02-041996-12-24The Johns Hopkins UniversityInhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US6461607B1 (en)1998-08-242002-10-08Ganeden Biotech, Inc.Probiotic, lactic acid-producing bacteria and uses thereof
BR112012003103A2 (en)2009-08-102016-04-19Univ Texas treatment of tumor astrocyte cells with endothelin receptor inhibitor
US9763982B2 (en)2010-06-292017-09-19The Regents Of The University Of CaliforniaDepletion of cancer stem cells
EP3012271A1 (en)2014-10-242016-04-27EffimuneMethod and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
KR101697473B1 (en)*2014-11-262017-01-18주식회사 녹십자랩셀Method for Preparation of Natural Killer Cells Using T Cells
US20180171298A1 (en)*2015-06-302018-06-21CellectisMethods for improving functionality in nk cell by gene inactivation using specific endonuclease

Also Published As

Publication numberPublication date
EP3582856A4 (en)2021-03-10
US20200306300A1 (en)2020-10-01
KR20190129046A (en)2019-11-19
WO2018152340A1 (en)2018-08-23
US20240165152A1 (en)2024-05-23
CN110799201A (en)2020-02-14
AU2018221745A1 (en)2019-10-03
CA3059058A1 (en)2018-08-23
JP7374769B2 (en)2023-11-07
US20250049859A1 (en)2025-02-13
JP2020507343A (en)2020-03-12
JP2024010093A (en)2024-01-23
EP3582856A1 (en)2019-12-25

Similar Documents

PublicationPublication DateTitle
SG11201908472VA (en)Compositions and methods for activating nk cells
SG11201809857TA (en)Anti-CTLA-4 Antibodies
SG11201907857RA (en)Edible and biodegradable utensils
SG11201907650RA (en)Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201901628XA (en)Methods and compositions for spinal cord cells
SG11201808622SA (en)Chimeric receptors to flt3 and methods of use thereof
SG11201910019PA (en)Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201811184UA (en)Lag -3 binding members
SG11201806485RA (en)Pyrrolobenzodiazepine conjugates
SG11201807252QA (en)Anti-lag-3 antibodies
SG11201809912UA (en)Hybrid carriers for nucleic acid cargo
SG11201906660TA (en)Anti-tgf-beta antibodies and their use
SG11201809374VA (en)Cd40l-fc fusion polypeptides and methods of use thereof
SG11201909963YA (en)Methods for treating dravet syndrome
SG11201810887UA (en)Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201805950UA (en)Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201809534UA (en)Methods of treating autoimmune disease using allogeneic t cells
SG11201909303TA (en)Point of delivery cold slurry generation
SG11201903427UA (en)Deodorizing agent comprising zinc neodecanoate
SG11201906807VA (en)Compositions and methods for promoting hair growth with mpc1 inhibitors
SG11201910195WA (en)Methods for trapping and barcoding discrete biological units in hydrogel
SG11201909003YA (en)Integrated vascular access device and anchor pad
SG11201909501TA (en)Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
SG11201901172QA (en)A method for manufacturing a fuel component
SG11201906383WA (en)A layered medical data computer architecture

[8]ページ先頭

©2009-2025 Movatter.jp